• 1
    Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115: 457469.
  • 2
    Borrelli E, Roux-Lombard P, Grau GE, Girardin E, Ricou B, Dayer J, et al. Plasma concentrations of cytokines, their soluble receptors, and antioxidant vitamins can predict the development of multiple organ failure in patients at risk. Crit Care Med 1996; 24: 392397.
  • 3
    Giron-Gonzalez JA, Martinez-Sierra C, Rodriguez-Ramos C, Macias MA, Rendon P, Diaz F, et al. Implication of inflammation-related cytokines in the natural history of liver cirrhosis. Liver Int 2004; 24: 437445.
  • 4
    Moreau R, Hadengue A, Soupison T, Kirstetter P, Mamzer MF, Vanjak D, et al. Septic shock in patients with cirrhosis: hemodynamic and metabolic characteristics and intensive care unit outcome. Crit Care Med 1992; 20: 746750.
  • 5
    Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 13031310.
  • 6
    Byl B, Roucloux I, Crusiaux A, Dupont E, Deviere J. Tumor necrosis factor alpha and interleukin 6 plasma levels in infected cirrhotic patients. Gastroenterology 1993; 104: 14921497.
  • 7
    Heller J, Sogni P, Barriere E, Tazi KA, Chauvelot-Moachon L, Guimont MC, et al. Effects of lipopolysaccharide on TNF-alpha production, hepatic NOS2 activity, and hepatic toxicity in rats with cirrhosis. J Hepatol 2000; 33: 376381.
  • 8
    Tazi KA, Bieche I, Paradis V, Guichard C, Laurendeau I, Dargere D, et al. In vivo altered unfolded protein response and apoptosis in livers from lipopolysaccharide-challenged cirrhotic rats. J Hepatol 2007; 46: 10751088.
  • 9
    Deviere J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, et al. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. HEPATOLOGY 1990; 11: 628634.
  • 10
    Riordan SM, Skinner N, Nagree A, McCallum H, McIver CJ, Kurtovic J, et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. HEPATOLOGY 2003; 37: 11541164.
  • 11
    Tazi KA, Moreau R, Herve P, Dauvergne A, Cazals-Hatem D, Bert F, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine upregulation in cirrhotic rats: role of Akt signaling. Gastroenterology 2005; 129: 303314.
  • 12
    Tazi KA, Quioc JJ, Saada V, Bezeaud A, Lebrec D, Moreau R. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol 2006; 45: 280289.
  • 13
    Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins: isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981; 67: 827837.
  • 14
    Zambon S, Orlando R, Sartore G, Bassi A, Manzato E, Crepaldi G. The lipoprotein composition of plasma and ascitic fluid in liver cirrhosis. Eur J Clin Invest 1995; 25: 143148.
  • 15
    Fraunberger P, Pilz G, Cremer P, Werdan K, Walli AK. Association of serum tumor necrosis factor levels with decrease of cholesterol during septic shock. Shock 1998; 10: 359363.
  • 16
    Hubsch AP, Casas AT, Doran JE. Protective effects of reconstituted high density lipoprotein in rabbit gram-negative bacteremia models. J Lab Clin Med 1995; 126: 548558.
  • 17
    Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 1993; 90: 1204012044.
  • 18
    McDonald MC, Dhadly P, Cockerill GW, Cuzzocrea S, Mota-Filipe H, Hinds CJ, et al. Reconstituted high-density lipoprotein attenuates organ injury and adhesion molecule expression in a rodent model of endotoxic shock. Shock 2003; 20: 551557.
  • 19
    Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van der Poll T, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184: 16011608.
  • 20
    Ramirez MJ, Ibanez A, Navasa M, Casals E, Morales-Ruiz M, Jimenez W, et al. High-density lipoproteins reduce the effect of endotoxin on cytokine production and systemic hemodynamics in cirrhotic rats with ascites. J Hepatol 2004; 40: 424430.
  • 21
    Thabut D, Tazi KA, Bonnefont-Rousselot D, Aller M, Farges O, Guimont MC, et al. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. HEPATOLOGY 2007; 46: 18931906.
  • 22
    Ferrero E, Jiao D, Tsuberi BZ, Tesio L, Rong GW, Haziot A, et al. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Natl Acad Sci U S A 1993; 90: 23802384.
  • 23
    Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice. Immunity 1996; 4: 407414.
  • 24
    Buechler C, Ritter M, Quoc CD, Agildere A, Schmitz G. Lipopolysaccharide inhibits the expression of the scavenger receptor Cla-1 in human monocytes and macrophages. Biochem Biophys Res Commun 1999; 262: 251254.
  • 25
    Vishnyakova TG, Bocharov AV, Baranova IN, Chen Z, Remaley AT, Csako G, et al. Binding and internalization of lipopolysaccharide by Cla-1, a human orthologue of rodent scavenger receptor B1. J Biol Chem 2003; 278: 2277122780.
  • 26
    Camps J, Simo JM, Guaita S, Ferre N, Joven J. Altered composition of lipoproteins in liver cirrhosis compromises three homogeneous methods for DL cholesterol. Clin Chem 1999; 45: 685688.
  • 27
    Gomez F, Camps J, Simo JM, Ferre N, Joven J. Agreement study of methods based on the elimination principle for the measurement of LDL- and HDL-cholesterol compared with ultracentrifugation in patients with liver cirrhosis. Clin Chem 2000; 46: 11881191.
  • 28
    Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499502.
  • 29
    Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649683.
  • 30
    Fraunberger P, Schaefer S, Werdan K, Walli AK, Seidel D. Reduction of circulating cholesterol and apolipoprotein levels during sepsis. Clin Chem Lab Med 1999; 37: 357362.
  • 31
    Albillos A, de la Hera A, Gonzalez M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. HEPATOLOGY 2003; 37: 208217.
  • 32
    Albillos A, de-la-Hera A, Alvarez-Mon M. Serum lipopolysaccharide-binding protein prediction of severe bacterial infection in cirrhotic patients with ascites. Lancet 2004; 363: 16081610.
  • 33
    Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPShost cell interactions. J Endotoxin Res 2005; 11: 225229.
  • 34
    Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994; 180: 10251035.
  • 35
    Fearns C, Kravchenko VV, Ulevitch RJ, Loskutoff DJ. Murine CD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharide. J Exp Med 1995; 181: 857866.